EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

Víctor A Arrieta, Crismita Dmello, Daniel J McGrail, Daniel J Brat, Catalina Lee-Chang, Amy B Heimberger, Dhan Chand, Roger Stupp, Adam M Sonabend

Journal of Clinical Investigation · 17.01.2023 · 133 (2)

DOI: 10.1172/jci163447 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.01.2023. Verfasst von Víctor A Arrieta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Glioblastoma, Glioma. Die Arbeit wurde bisher 248-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing great interest in the neuro-oncology community. While several reports show that subsets of patients with glioma exhibit durable responses to immunotherapy, the efficacy of this treatment has not been observed for unselected patient populations, preventing its broad clinical implementation for gliomas and glioblastoma (GBM). To exploit the maximum therapeutic potential of ICB for patients with glioma, understanding the different aspects of glioma-related tumor immune responses is of critical importance. In this Review, we discuss contributing factors that distinguish subsets of patients with glioma who may benefit from ICB. Specifically, we discuss (a) the complex interaction between the tumor immune microenvironment and glioma cells as a potential influence on immunotherapy responses; (b) promising biomarkers for responses to immune checkpoint inhibitors; and (c) the potential contributions of peripheral immune cells to therapeutic responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaGliomaHumansImmune Checkpoint InhibitorsPrecision MedicineImmunotherapyTumor Microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Program of Combined Studies in Medicine (PECEM), Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
  • Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Center for Immunotherapy and Precision Immuno-Oncology and.
  • Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Arrieta, V. A., Dmello, C., McGrail, D. J., Brat, D. J., Lee-Chang, C., Heimberger, A. B., Chand, D., Stupp, R., & Sonabend, A. M. (2023). Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. Journal of Clinical Investigation, 133(2). https://doi.org/10.1172/jci163447

Vancouver

Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. Journal of Clinical Investigation. 2023;133(2). doi:10.1172/jci163447

BibTeX
@article{Arrieta2023,
  author = {Arrieta, Víctor A and Dmello, Crismita and McGrail, Daniel J and Brat, Daniel J and Lee-Chang, Catalina and Heimberger, Amy B and Chand, Dhan and Stupp, Roger and Sonabend, Adam M},
  title = {Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {2},
  doi = {10.1172/jci163447}
}
Kostenlos starten →